Lumos Diagnostics (ASX: LDX) Expands FebriDx US Footprint to 215 Sites

Lumos Diagnostics Holdings has expanded the US footprint of its FebriDx point-of-care test, with the number of live sites rising to 215 from 170 in July as several large urgent-care groups move closer to broader adoption.

The company said two top-100 US urgent-care groups have committed to network rollouts across more than 40 sites combined. Both are owned and operated by major US health systems.

A further two top-100 groups are validating FebriDx across more than 45 sites in aggregate, also within major health-system networks.

The update covers progress since Lumos’ ASX releases on July 21 and July 27.

Live Network Expands Across 26 States

The two customers now in rollout comprise an integrated regional health system and an academic medical centre and health system. Lumos did not identify either organisation.

The deployments have expanded the company’s live network to 215 sites across 26 US states.

Lumos estimates those sites collectively handle between 900,000 and 1.2 million acute respiratory illness visits each year, based on an assumed 4,000 to 5,500 relevant visits per urgent-care site.

That figure represents the potential addressable patient pool rather than a forecast of FebriDx testing volumes.

FebriDx is designed to help clinicians distinguish between bacterial and viral acute respiratory infections at the point of care. Lumos is targeting uses including prescribing decisions, antibiotic stewardship and patient referral.

The company previously reported payment coverage above 90% at US$41.38 per test, based on data available as of July 27. Future reimbursement updates will depend on formal reporting from Acuity MD.

Evaluation Pipeline Reaches 405 Sites

The number of sites conducting clinical and economic evaluations has increased to 405 from 350.

Those sites represent an estimated 1.6 million to 2.2 million acute respiratory illness visits annually and include five of the 100 largest urgent-care groups in the US.

The evaluations assess clinical performance, reimbursement, workflow integration and health-economic outcomes before customers decide whether to proceed to broader deployment.

Lumos categorises its commercial pipeline across four stages: qualification, evaluation, network rollout and standardised adoption.

The final stage involves embedding FebriDx into standing orders, triage protocols or other routine clinical pathways.

The company is focusing on the 100 largest US urgent-care groups, which it estimates account for about 40% of all urgent-care sites nationally.

WellStreet Provides Rollout Model

Lumos said the latest deployments follow a similar pathway to its rollout with existing customer WellStreet Urgent Care.

That program progressed from an initial pilot to deployment across 44 sites.

WellStreet operates more than 165 locations, leaving scope for further expansion, although Lumos did not announce any additional WellStreet rollout in the latest update.

All US sales of FebriDx are made through exclusive distributor Phase Scientific, with Lumos recognising revenue when products are shipped to the distributor.

The company did not disclose order volumes, test sales, contract values or revenue associated with the latest rollouts and evaluations.